Jacob Van Naarden bought $647K of Eli Lilly and (LLY)
Executed Aug 13 2025, disclosed Aug 13 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Aug 13 2025), the stock returned +16.5% (delay-adjusted); from the execution session (Aug 13 2025), +16.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Jacob Van Naarden (EVP & Pres., Lilly Oncology) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Eli Lilly and Company (LLY). Across 1 priced purchase filing, the average 21-session return was +16.5% from execution and +16.5% from disclosure (delay-adjusted; derived). The largest single filing was $647K of LLY (1,000 sh × $647.36, as filed), executed Aug 13 2025.
Healthcare · Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Jap…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→